Related Experiment Videos
Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma.
J G Strickler1, M W Audeh, C M Copenhaver
1Department of Pathology, Stanford University Medical Center, CA 94305.
Cancer
|May 1, 1988
Summary
Immunophenotypic analysis differentiated plasmacytoma/multiple myeloma from immunoblastic lymphoma using antibody panels. Proliferation marker Ki-67 correlated with prognosis in these B-cell malignancies.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Plasmacytoma (PC) and multiple myeloma (MM) are plasma cell neoplasms, while immunoblastic lymphoma (IL) is a B-cell lymphoma.
- Distinguishing between PC/MM and IL can be challenging based on morphology alone.
Purpose of the Study:
- To investigate the immunophenotypic differences between PC/MM and IL using a panel of monoclonal antibodies.
- To assess the utility of Ki-67 as a proliferation marker in relation to prognosis.
Main Methods:
- Analysis of frozen tissue sections from four PC, six MM, and nine IL cases.
- Application of a large panel of monoclonal antibodies, including lineage-specific and proliferation markers (Ki-67).
Main Results:
- PC/MM cases showed characteristic staining with alpha/gamma and T10, and lacked staining for mu, leukocyte common antigen, B-cell markers (B1, T015, 4G7, 6A4), and Ia.
- IL cases typically stained positive for mu/gamma, leukocyte common antigen, B-cell markers, and Ia, but negative for alpha and T10.
- Ki-67 staining was significantly lower in PC/MM compared to IL and inversely correlated with favorable clinical outcomes.
Conclusions:
- A panel of monoclonal antibodies can aid in distinguishing PC/MM from IL.
- Ki-67 reactivity may serve as a prognostic indicator in these B-cell malignancies.